Janux Therapeutics, Inc.
JANXNASDAQHealthcare● Active
$13.56
+$0.20(+1.50%)
Market Cap$826947840
P/E Ratio—
52W High$35.34
52W Low$12.12
Janux Therapeutics, Inc. (JANX) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · JANX · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $10.00M | $10.59M | $8.08M | $8.61M | $3.64M |
| Cost of Revenue | $2.03M | $2.06M | $1.96M | $0.84M | $0.00M |
| Gross Profit | $7.97M | $8.53M | $6.13M | $7.77M | $3.64M |
| Gross Margin %(computed) | 79.71% | 80.54% | 75.81% | 90.23% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $125.90M | $68.39M | $54.92M | $53.44M | $26.24M |
| G&A Expenses | $41.77M | $41.05M | $26.14M | $22.26M | $10.33M |
| Total Operating Expenses | $165.64M | $107.38M | $79.11M | $74.86M | $36.57M |
| Operating Income | ($157.67M) | ($98.85M) | ($72.98M) | ($67.09M) | ($32.93M) |
| Operating Margin %(computed) | — | -933.58% | -902.87% | -779.04% | -905.39% |
| Interest Income | $44.04M | $29.85M | $14.69M | $4.03M | $0.26M |
| Interest Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($113.63M) | ($68.99M) | ($58.29M) | ($63.06M) | ($32.67M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($113.63M) | ($68.99M) | ($58.29M) | ($63.06M) | ($32.67M) |
| Net Margin %(computed) | — | -651.62% | -721.18% | -732.22% | -898.32% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-1.83 | $-1.28 | $-1.32 | $-1.52 | $-0.79 |
| Wtd Avg Shares | 61.97M | 53.75M | 44.02M | 41.47M | 41.24M |
| EBITDA | ($111.60M) | ($96.79M) | ($71.02M) | ($66.25M) | ($32.82M) |
| EBITDA Margin %(computed) | — | -914.12% | -878.68% | -769.28% | -902.28% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · M
Explore more Janux Therapeutics, Inc. data
About Janux Therapeutics, Inc. (JANX) Income Statement
Janux Therapeutics, Inc. (JANX) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, JANX reported revenue of $0.01B, gross profit of $0.01B (gross margin 79.71%), and net income of ($0.11B) — a net profit margin of -1136.25%.
Frequently asked questions
JANX · 4 questionsJanux Therapeutics, Inc. (JANX) reported revenue of $0.01B for 2025, down 5.6% year-over-year.
JANX revenueJANX salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08